Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV–HCV co-infected patients: final results of the Spanish BOC HIV–HCV Study | Zendy

Montserrat Laguno | Zendy; M. A. von Wichmann | Zendy; Eva Van den Eynde | Zendy; Jordi Navarro | Zendy; Carmen Luna | Zendy; Javier Murillas | Zendy; Sergio Veloso | Zendy; Marı́a Martı́nez-Rebollar | Zendy; Josep M. Guardiola | Zendy; Antoni Jou | Zendy; J. L. Gómez-Sirvent | Zendy; M. Cervantes | Zendy; Juan A. Pineda | Zendy; Soledad LópezCalvo | Zendy; A. Carrero | Zendy; Marisa Montes | Zendy; Elisabet Deig | Zendy; A. Tapiz | Zendy; Juan Diego Ruíz-Mesa | Zendy; Anna Cruceta | Zendy; Elisa de Lazzari | Zendy; Josep Mallolas | Zendy

Open Access

Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV–HCV co-infected patients: final results of the Spanish BOC HIV–HCV Study

Author(s) -

Montserrat Laguno,

M. A. von Wichmann,

Eva Van den Eynde,

Jordi Navarro,

Carmen Luna,

Javier Murillas,

Sergio Veloso,

Marı́a Martı́nez-Rebollar,

Josep M. Guardiola,

Antoni Jou,

J. L. Gómez-Sirvent,

M. Cervantes,

Juan A. Pineda,

Soledad LópezCalvo,

A. Carrero,

Marisa Montes,

Elisabet Deig,

A. Tapiz,

Juan Diego Ruíz-Mesa,

Anna Cruceta,

Elisa de Lazzari,

Josep Mallolas

Publication year - 2016

Publication title -

international journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.278

H-Index - 89

eISSN - 1878-3511

pISSN - 1201-9712

DOI - 10.1016/j.ijid.2016.10.028

Subject(s) - medicine , ribavirin , boceprevir , pegylated interferon , gastroenterology , discontinuation , hepatitis c virus , hepatitis c , combination therapy , adverse effect , cirrhosis , viral load , immunology , human immunodeficiency virus (hiv) , virus

Boceprevir (BOC) was one of the first oral inhibitors of hepatitis C virus (HCV) NS3 protease to be developed. This study assessed the safety and efficacy of BOC+pegylated interferon-α2a/ribavirin (PEG-IFN/RBV) in the retreatment of HIV-HCV co-infected patients with HCV genotype 1.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research